We propose methods to determine the minimum number of subjects remaining at risk after which Kaplan-Meier survival plots for time-to-event outcomes should be curtailed, as, once the number remaining at risk drops below this minimum, the survival estimates are no longer meaningful in the context of the investigation. The size of the decrease of the Kaplan-Meier survival estimate S(t) at time t if one extra event should occur is considered in two ways. In the first approach, the investigator sets a maximum acceptable absolute decrease in S(t) should one extra event occur. In the second, a minimum acceptable number of subjects still at risk is calculated by comparing the size of the decrease in S(t) if an extra event should occur to the variability of the survival estimate had all subjects been followed to that time (confidence interval approach). We recommend calculating both limits for the number still at risk and then making an informed choice in the context of the particular investigation. We explore further how the amount of information actually available can assist in considering issues of data maturity for studies whose outcome of interest is a survival percentage at a particular time point.
Introduction and motivation
For studies with time-to-event outcomes, the associated survival estimates need to account for censoring which occurs when individuals do not experience the event of interest during the period of their follow-up. The Kaplan-Meier method produces survival estimates S(t) at time t which are then displayed graphically as a Kaplan-Meier plot (survival curve) 1, 2 . This curve is a step function, decreasing each time an event is observed. It is used extensively in medicine and health sciences where time-to-event outcomes are common, and to illustrate data describing disease history available from clinical registries, to monitor the failure of medical devices, in areas of health economics and so on. A common application of the Kaplan-Meier approach is to obtain estimates and associated confidence intervals (CIs) of the probability of remaining event-free at specific time points. These estimates (a) help inform clinical practice and choice of therapy; (b) assist in evaluating new therapies; and (c) facilitate the evaluation of public health policies in relation to resources or directions required to reduce disease burdens in populations of interest.
The uncertainty of a survival estimate increases as the number in the sample remaining at risk decreases over time. Survival estimates are often presented over the full duration of the followup period, when more thought could be given to the value of the information displayed [3] [4] [5] , a point highlighted by Carter 6 . Therefore, even though the estimates can be calculated, the question arises as to whether they should be included in the Kaplan-Meier plot? In other words, how far in time should the Kaplan-Meier plot be extended? This question is directly related to the number of events which have been observed, and the extent of the study follow-up (data maturity).
In prospective clinical trials, data maturity is one of the design parameters used to determine sample size. Ideally such studies do not report their results until the predetermined follow-up time is reached. The issue of data maturity is crucial in prospective and retrospective observational studies such as disease registries and epidemiological investigations, especially when the focus is the survival estimate at a clinically important time point. When long-term follow-up is of interest, and the evaluation time has not been pre-specified, a Kaplan-Meier plot should be curtailed before the number of subjects remaining at risk is too small to meaningfully interpret the survival estimates. Guidelines regarding how far in time to extend the Kaplan-Meier plot would help to minimise interpretations which may be misleading. Pocock et al 7 , suggested "In general, we recommend that survival plots be halted once the proportion of patients free of an event, but still in follow-up, becomes unduly small…. It will often be reasonable to curtail the plot when only around 10-20% are still in follow-up." However, this guideline is problematic if the original study size is large: for example, 10-20% of a sample of 500 subjects corresponds to 50-100 subjects still at risk. Clark et al's measure of data completeness 8 provides an index of the actual followup, which may be reduced by drop-out and censoring, relative to the expected follow-up if all subjects were accounted for to the end of the study. This index helps guide the interpretation of trial results. However in many observational cohorts, and especially clinical registries, the expected follow-up time for individuals in the cohort is unknown. To address some of the drawbacks relating to uncertainty and censoring, methods have been proposed to adjust the variance of the survival estimate to account for the reduction in the number at risk due to censoring resulting in modified variance estimators [9] [10] [11] [12] [13] [14] .
Apart from the issue of precision of the survival estimate when only a small number of subject are still at risk, the interpretation of the survival estimate may suffer from representiveness bias and compromise generalizability. For example, the trial of radioembolization for metastatic liver cancer in a high-risk patient cohort 15 reported one patient (receiving the intervention) remaining disease free for over 8 years, while for all the other patients the disease-free survival (DFS) was < 5.5 years. Such a long DFS was considered extraordinary, but in subsequent similar studies with over 1000 (lower risk) patients and more modern chemotherapy 16 a DFS of this magnitude could not be achieved. This individual was clearly atypical of this population and long term DFS rates based on this study would be misleading.
A related question of data maturity is 'For how long should subjects be followed once recruitment has been completed in studies whose primary outcome is the proportion of subjects remaining event-free at a particular time?' This question often arises in studies of surgical techniques, organ transplantation, medical devices, paediatric therapies and radiotherapy where comparisons of 5 or 10-year survival rates are of more clinical interest than hazard ratios [17] [18] [19] . Consider, a study of adjuvant therapy after renal transplantation which has just completed accrual with the outcome 
Δ(t) = 100S(t)/n(t)
is defined for n(t) ≥ 1.
We will refer to Δ(t)=100S(t)/n(t) as the sensitivity index of the survival estimate at time t.
If the estimated event-free survival probability at time t is high and few subjects remain at risk, then the sensitivity index will be large, indicating the potential for a sharp drop in the Kaplan-Meier plot due to a single extra event. This is illustrated in figure 1 using data from the I-ELCAP study 20 
This criterion is particularly helpful for studies exhibiting a high degree of 'early' censoring, (patients at risk not having sufficient follow-up over the study duration) as in the I-ELCAP study. When considering clinical practice or developing guidelines, Δ * should be small, <1% say (for example when using a clinical registry with large patient numbers). For other clinical studies (with 'small' or 'moderate' sample sizes) larger threshold values (2.5% or 5%) might be considered acceptable.
Statistical packages routinely provide details of n(t) and S(t) at all censoring or event times t.
The survival plot can be extended to t and satisfy Criterion 1 provided n(t) > 100S(t)/ Δ * . When the survival curve is close to the x axis, this issue may not be so important 3, 21 .
Criterion 2. Δ(t) < width of one-sided 95% CI for %survival based on 'full information'
Criterion 1 however does not consider the uncertainty present in a survival estimate at the time point of interest, t. If there has been no censoring up to or including time t, then all N subjects enrolled in a study will have been followed up to or past time t. In this optimal situation of full information at time t, the standard error SE(t) of the estimate S(t) is smaller than if some censoring had occurred prior to time t. When there is full information at time t, SE(t) is simply the standard error of a binomial proportion S(t) with sample size N (the number of subjects entering the study), that is SE(t) = √{S(t)[1-S(t)]/N}. Furthermore, the lower boundary of the one-sided 95% confidence interval (CI) for the estimated percentage of subjects event-free in the case of full information at time t is 100*[S(t)-1.645*√{S(t)[1-S(t)]/N}] where 1.645 is the upper 5% quantile (often written z1-α) of the standard normal distribution. We refer to this boundary as the full information one-sided 95% confidence boundary of %survival.
Our second criterion requires the sensitivity index Δ(t) to be no larger than the width of the full information one-sided 95%CI for the %survival at t, that is
This criterion implies that one extra event observed just after time t would not decrease the estimated %survival to below its full information one-sided 95% confidence boundary at time t.
We interpret this as evidence that enough subjects remain at risk at time t for the meaningful interpretation of the Kaplan-Meier plot.
The relationship between the study size N and the minimum number at risk required to satisfy (2) is shown in figure 2 for S(t) =0.1,0.2, …, 0.95. The different levels of S(t) reflect the different amounts of censoring present. Again, the quantities N and S(t) required in (2) are routinely produced by statistical packages. If a less conservative bound is desired for Criterion 2, the full information lower one-sided 97.5% CI can be used instead. In this case the divisor of 1.645 in (2) is replaced by 1.96. and 50% in the control with 4 subjects still at risk. The sensitivity index at 60 months is 11% for the CPAP group and 13% for the control group. The full information CI approach of Criterion 2 suggests the curve be curtailed when there is a minimum of 10 intervention-group and 7 control patients at risk. If we also require the transplant-free estimate not to decrease by more than Δ * =5% in each group, the curve should be curtailed at 48 months, when S(48) = ~0.64 and n(48)=20
giving a sensitivity index of 3.2% in the CPAP, and S(48) = ~0.55 and n(48)=19 giving a sensitivity index 2.9% in the control group (the 48-month transplant rate is estimated at 55%).
The third example, the MA 17 trial, the overall and disease-free survival in breast cancer patients receiving an additional 5 years of letrozole after 5 years of tamoxifen or placebo 23 was investigated with a sample size over 5000 patients. The Kaplan-Meier plots were extended to 48 months, where less than 0.5% of patients were being followed up at this time. The results of these three studies are summarised in 
Duration of follow-up after recruitment has completed
The second data maturity issue, namely at what point during the follow-up phase of a study it would be appropriate to perform statistical analyses, is a concern in clinical studies whose outcome of interest is the survival proportion (or difference) at a pre-specified time t. As alluded to earlier the estimates at t also need to well reflect the patient population and not be unduly we may wish to exclude those patients who are lost to follow-up and will never be observed at t).
This variance ratio will be expressed as a percentage and denoted I(t). Clearly 0%≤ I(t) ≤ 100% and the smaller the ratio, the less mature the data. We note that the inverse of the ratio is sometimes referred to as the variance inflation ratio.
The sample size for a study designs are typically based on 80% or 90% power and assume complete data at time t of interest. This power calculation is related to the probability of a type II error, β, and obtained from the quantiles of the standard normal distribution denoted by z1-β. For While we have used just the ALND group to illustrate these ideas, in practice, all these quantities should only be obtained from pooled data (blinded to treatment allocation) to ensure no bias is introduced into the decision as to whether the data should be analysed at the current study duration. It is crucial that investigators and statisticians remain blinded to treatment allocation prior to these decisions being made. Decisions regarding study accrual/follow-up should be made prior to study commencement and decisions to stop a study prior to the accrual being met should be made by an independent data safety and monitoring committee who would assess the totality of the evidence before making their recommendations. Such committees would also review pooled data before requesting unblinded information.
We can also apply these ideas to the I-ELCAP study. The median follow-up for the observation group is 46 months (based on the reverse Kaplan-Meier method 26 ) and, if the outcome of interest is the percentage of patients surviving at 72-months, the survival estimate is 81% with a variance of 0.0215 2 . The full information variance at 72-months is (0.81*0.19)/484 (assuming no losses to follow-up), I(72) is 69% and I(120) is 41%. We note that 51 out of 410 patients (12.2%) not having an event have been followed to 72 months and 2 out of 409 (0.5%) have been followed to 120 months. In this example where the prime interest in the precision of the S(t), the number at risk at t together with I(t) will help the interpretation of the maturity of follow-up at these times. 12 The change in the change in study power based on different levels of I(t) for study designs based power of 80% 85% and 90% is shown in figure 3 . We defined the sensitivity index Δ(t) of the Kaplan Meier estimate S(t) at a t, as the decrease of the %survival estimate had one extra event occurred immediately post t. We propose two criteria to assess Δ(t). The first sets a maximum acceptable threshold Δ * for the sensitivity index in the context of the investigation. The second criterion restricts Δ(t) to be no larger than the width of the full information one-sided 95% CI for the %survival at t. These approaches assist investigators in deciding when to curtail the Kaplan-Meier plot and so avoid potential misrepresentation of the survival estimates. The 95% confidence interval at t is commonly obtained from Greenwoods formula but this approach has limitations 9, 12 . When compared to the recommendation of Pocock 7 , the proposed strategies are less conservative.
More recently Fay et al. 11 have proposed a method which adjusts the width of the confidence interval to account for changes in the number at risk based on the product of beta random variables. While the method is methodologically complex, with calculations currently only available in the statistical package R, it nevertheless illustrates the increase in uncertainty with increased censoring. However, when there are multiple curves being presented (as in the ADAPT study 27 ), the benefit of the visual representation can be masked with the multiple confidence bands. Fay et al's lower one-sided 95% CI is shown as the shaded area in figure 1 ; the lower limit at 120 months being 0.21 and, at 84 months, 0.70. These values are larger than 0.76, the value given at both times by the Greenwood method. While these intervals demonstrate the uncertainty in the estimates they do not provide guidelines as to when survival plots should be curtailed. Our approach provides a framework for interpretation of survival estimates at specified time points based on both the uncertainty and the number at risk at these points.
This approach has applicability to a wide range of practical problems, and does not rely on 
Conclusion
We provide a simple and effective framework to gauge the maturity of data at different followup times to inform researchers as to which follow-up time provides sufficient information to allow sensible interpretation of survival estimates. Two approaches for when to curtail the Kaplan-Meier plot are proposed, both related to the decrease in the %survival estimate if one further event were to occur. The minimum required number at risk at any time point based on the full information CI has a straightforward interpretation and can be easily calculated from the output provided by common statistical packages. We provide an approach to ascertain the actual information based on the current number of events and current follow-up times in a clinical study.
This allows investigators to determine the statistical power certain comparisons may have if
Key Messages
• The information provided by the Kaplan-Meier (KM) curve at a particular time point is dependent on the number of subjects at risk at this time point. If there are only a few patients at risk, then one single extra event will make a substantial impact on the distance by which the KM curve decreases.
• Data maturity is explored with respect to two problems: (i) how far in time a KM curve should be extended and (ii) at what point in a clinical study, prior to achieving complete follow-up, can it still be appropriate to report results.
• For (i), a minimum desirable number at risk is readily obtained if the drop in the survival estimate at time t should one extra event occur is required to be less than a pre-determined threshold. To ensure this drop remains below the threshold, large survival estimates require more patients remaining at risk than smaller ones.
• An alternative approach to (i) is to require that the decrease in the survival estimate at time t should one extra event occur does not exceed the width of the one-sided 95% CI for survival based on 'full information' if all the data were available up to the time of interest.
• For (ii), when follow-up is incomplete at some time point, the variance of the KM estimate is larger than if there had been complete follow-up. The variance ratio represents the proportion of actual information available at the time point. It can be used in comparative studies to determine the potential statistical power if study results are reported for that time point without further followup.
• The amount of current information available and the percentage of complete follow-up can be used to both plan the follow-up duration of the current study to ensure that a study attains an acceptable level of actual information or sufficient expected power prior to analysis of the results. Shaded area: Fay and Brittain 95% one-sided pointwise confidence bands
Figure legend

Figure 2
Minimum number of patients at risk for different sample sizes for values of the Kaplan-Meier curve, S(t) from 0.1 to 0.95
Figure 3
Levels of statistical power for percentages of actual information available in study designs having 80%, 85% and 90% power with complete information 
